Stockscreener 앱 받기
3.63
5.52%
0.19
시간 외 거래:
3.62
-0.010
-0.28%
전일 마감가:
$3.44
열려 있는:
$3.45
하루 거래량:
7.37M
Relative Volume:
0.82
시가총액:
$1.19B
수익:
$32.77M
순이익/손실:
$-440.22M
주가수익비율:
-2.1737
EPS:
-1.67
순현금흐름:
$-400.48M
1주 성능:
+2.54%
1개월 성능:
-30.99%
6개월 성능:
-62.23%
1년 성능:
-74.26%
1일 변동 폭
$3.42
$3.66
1주일 범위
$3.33
$3.69
52주 변동 폭
$3.33
$15.18
Iovance Biotherapeutics Inc Stock (IOVA) Company Profile
명칭
Iovance Biotherapeutics Inc
전화
(650) 260-7120
주소
825 INDUSTRIAL ROAD, SAN CARLOS
IOVA을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
IOVA
Iovance Biotherapeutics Inc
|
3.63 | 1.19B | 32.77M | -440.22M | -400.48M | -1.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
502.55 | 131.41B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
635.83 | 72.26B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
593.47 | 36.20B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
271.02 | 35.08B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
262.60 | 28.24B | 3.81B | -644.79M | -669.77M | -6.24 |
Iovance Biotherapeutics Inc Stock (IOVA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-10-24 | 개시 | UBS | Buy |
| 2024-07-29 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2023-11-20 | 개시 | Goldman | Buy |
| 2023-09-18 | 재확인 | Barclays | Overweight |
| 2023-05-30 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2023-03-27 | 재개 | Wells Fargo | Equal Weight |
| 2023-01-27 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2022-12-09 | 다운그레이드 | Goldman | Buy → Neutral |
| 2022-10-31 | 개시 | Guggenheim | Neutral |
| 2022-08-18 | 재개 | Wells Fargo | Equal Weight |
| 2022-01-28 | 업그레이드 | Stifel | Hold → Buy |
| 2021-12-07 | 재개 | Cowen | Outperform |
| 2021-06-10 | 업그레이드 | JMP Securities | Mkt Perform → Mkt Outperform |
| 2021-05-20 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2021-05-19 | 다운그레이드 | JMP Securities | Mkt Outperform → Mkt Perform |
| 2021-05-19 | 다운그레이드 | Stifel | Buy → Hold |
| 2021-05-03 | 개시 | Truist | Buy |
| 2021-04-16 | 개시 | Goldman | Buy |
| 2021-03-08 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2020-12-15 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2020-10-06 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2020-04-22 | 개시 | Mizuho | Buy |
| 2020-03-04 | 개시 | Barclays | Overweight |
| 2020-02-26 | 재확인 | H.C. Wainwright | Buy |
| 2020-02-26 | 재확인 | Oppenheimer | Outperform |
| 2019-12-18 | 개시 | JMP Securities | Mkt Outperform |
| 2019-10-01 | 개시 | Stifel | Buy |
| 2019-04-29 | 개시 | Piper Jaffray | Overweight |
| 2019-02-28 | 재확인 | Chardan Capital Markets | Buy |
| 2019-02-07 | 개시 | Robert W. Baird | Outperform |
| 2018-12-31 | 재개 | B. Riley FBR | Buy |
| 2018-07-06 | 재확인 | Chardan Capital Markets | Buy |
| 2018-04-10 | 업그레이드 | B. Riley FBR, Inc. | Neutral → Buy |
| 2018-03-13 | 재확인 | B. Riley FBR, Inc. | Neutral |
| 2018-02-23 | 다운그레이드 | B. Riley FBR, Inc. | Buy → Neutral |
| 2018-01-25 | 재확인 | H.C. Wainwright | Buy |
| 2017-11-01 | 재확인 | B. Riley FBR, Inc. | Buy |
모두보기
Iovance Biotherapeutics Inc 주식(IOVA)의 최신 뉴스
Cell Therapy Veteran With 16 Successful Launches Joins TScan Leadership - StockTitan
Is Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) The Top Penny Stock That Will Skyrocket? - Insider Monkey
1 Stock Worth Buying Near Its 52-Week Low, According to Wall Street - MSN
3 Growth Stocks Wall Street Might Be Sleeping On -- But I'm Not - The Motley Fool
Iovance Biotherapeutics reports inducement grants under Nasdaq listing rule 5635(C)(4) - Marketscreener.com
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - GlobeNewswire
Iovance Expands Team: 308,710 Stock Options Awarded as Growth Accelerates - StockTitan
Iovance: The Company Makes It Hard To Estimate Revenue Growth (NASDAQ:IOVA) - Seeking Alpha
Philly weekly roundup: Iovance Biotherapeutics expands; Jawnt-SpotHero partnership; Mayor's budget address - Technical.ly
Is Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) the Most Oversold Penny Stocks to Buy According to Analysts? - Insider Monkey
Stifel maintains Buy on Iovance Biotherapeutics stock, $18 target By Investing.com - Investing.com Canada
Down Nearly 80% From Its High, Is Iovance Biotherapeutics Stock Too Cheap to Pass Up? - Yahoo
Melanoma Therapeutics Market to Reach $ 8.35 Bn by 2032Key - openPR
Proficio Capital Partners LLC Acquires New Stake in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) - Defense World
SBI Securities Co. Ltd. Acquires New Stake in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) - Defense World
Why Iovance Biotherapeutics Stock Zoomed More Than 5% Higher Today - AOL
Can Amtagvi Drive IOVA's Return To Glory - RTTNews
IOVA stock touches 52-week low at $3.62 amid market challenges - Investing.com
Iovance Biotherapeutics Inc to Host Earnings Call - ACCESS Newswire
Iovance Biotherapeutics (NASDAQ:IOVA) Given New $19.00 Price Target at The Goldman Sachs Group - MarketBeat
Iovance Biotherapeutics (NASDAQ:IOVA) Shares Down 5.8% After Analyst Downgrade - Defense World
Iovance Biotherapeutics (NasdaqGM:IOVA) Stock Dips 27% Despite Reaffirmed 2025 Earnings Guidance - Yahoo Finance
Iovance Biotherapeutics price target lowered to $30 from $34 at Chardan - Yahoo Finance
Iovance Biotherapeutics (NASDAQ:IOVA) Price Target Cut to $19.00 by Analysts at The Goldman Sachs Group - Defense World
Chardan Cuts Price Target on Iovance Biotherapeutics to $30 From $34, Keeps Buy Rating - Marketscreener.com
Rhumbline Advisers Has $2.86 Million Position in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) - Defense World
Iovance Biotherapeutics’ (IOVA) “Buy” Rating Reiterated at HC Wainwright - Defense World
Research Analysts Set Expectations for IOVA Q1 Earnings - Defense World
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Just Reported Earnings, And Analysts Cut Their Target Price - Simply Wall St
Iovance Biotherapeutics (NASDAQ:IOVA) Hits New 12-Month Low After Analyst Downgrade - Defense World
Iovance Biotherapeutics (NASDAQ:IOVA) Given "Buy" Rating at HC Wainwright - MarketBeat
Iovance Biotherapeutics Full Year 2024 Earnings: EPS Misses Expectations - Yahoo Finance UK
Robert W. Baird Cuts Iovance Biotherapeutics (NASDAQ:IOVA) Price Target to $20.00 - MarketBeat
Iovance Biotherapeutics Target of Unusually Large Options Trading (NASDAQ:IOVA) - Defense World
Iovance down 18% warning it could be impacted by geopolitical instability, inflation - MSN
Iovance Biotherapeutics (NASDAQ:IOVA) Releases Earnings Results, Hits Expectations - MarketBeat
Iovance Biotherapeutics’ Earnings Call Highlights Growth and Challenges - TipRanks
Iovance Biotherapeutics (NASDAQ:IOVA) Announces Quarterly Earnings Results, Meets Estimates - MarketBeat
New York State Common Retirement Fund Sells 98,840 Shares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) - MarketBeat
Forecasting The Future: 4 Analyst Projections For Iovance Biotherapeutics - Benzinga
Iovance's Q4: Execution Risks Mount As Infusion Growth Slows (Rating Downgrade) - Seeking Alpha
Truist Adjusts Price Target on Iovance Biotherapeutics to $15 From $25, Maintains Buy Rating - Marketscreener.com
IOVA Q4 Earnings Beat, Stock Down on Looming Economic Uncertainty - Yahoo Finance
IOVA stock touches 52-week low at $3.92 amid market challenges By Investing.com - Investing.com South Africa
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Q4 2024 Earnings Call Transcript - Insider Monkey
Iovance Biotherapeutics Q4 Loss Narrows, Revenue Rises -February 28, 2025 at 03:51 am EST - Marketscreener.com
Iovance Biotherapeutics Inc (IOVA) Q4 2024 Earnings Call Highlights: Strong Revenue and ... - Yahoo Finance
Iovance Biotherapeutics: Q4 Earnings Snapshot - The Washington Post
Iovance Biotherapeutics Reports Strong 2024 Earnings - TipRanks
Earnings call transcript: Iovance Biotherapeutics Q4 2024 results miss revenue forecasts - Investing.com India
Iovance Biotherapeutics, Inc. (IOVA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings - ACCESS Newswire
Iovance Biotherapeutics Inc (IOVA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.46%
0.90%
자본화:
|
볼륨(24시간):